The Zhitong Finance App learned that Kefu Healthcare (01187) rose more than 3% at the end of the session. As of press release, it rose 3.05% to HK$27.72, with a turnover of HK$4.0741 million.

According to the news, Corfu Healthcare recently released results. In the first three quarters, it achieved operating income of 3.191 billion yuan, an increase of 33.08% over the previous year; net profit to mother was 305 million yuan, an increase of 17.30% over the previous year. Huatai Securities pointed out that the volume of core categories in the first three quarters contributed to the rapid growth of the company's revenue. Optimistic about the continued release of self-developed ventilators, combined with increased contributions from CGM and Philips cooperative products, it is expected to drive continued rapid growth in performance.

According to public information, the company launched the AI ventilator C11 this year and launched the Dabai X3PRO lung disease ventilator together with Rongxin, and the product lineup continues to improve. Rongxin's household ventilator has obtained US FDA 510 (k) certification. Subsequent shipments are expected to be combined with the repurchase of mask consumables to promote the expansion of the business from equipment sales to “equipment+consumables+service”.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.